Cardiac Biomarkers W. Frank Peacock, M.D., FACEP Professor, Emergency Medicine Cleveland Clinic.

Slides:



Advertisements
Similar presentations
AST in AMI CK in AMI electrophoresis for CK and LD isoenzymes INH for CK-MB RIA for myoglobin WHO criteria for AMI CK-MB mass.
Advertisements

Early assessment of myocardial injury by joint measurement of TnT-hs and Copeptin (1) J. Teixeira, (2) P. Wotquenne, (2) V. D’Orio, (3) D. Gruson, (1)
Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K
Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Copeptin and high sensitive Troponins Discussion of NEJM publications on sensitive Troponins BRAHMS GmbH, August 2010.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Acute coronary syndrome : Risk stratification – markers of myocardial necrosis Paul Calle Emergency Department Ghent University Hospital Belgium.
What are the Causes of Troponin Elevation in non ACS? Carma Karam, MD Cardiologist AIHP, ACCA, FACC Clinique Médicale du Ring June 2011.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Myocardial infarction New concepts New definitions.
High Sensitivity Troponin
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
Chest Pain and Cardiac Emergencies Chest Pain and Cardiac Emergencies WelcomeChest PainCertaintySimulation.
“Acute Coronary Syndromes: Trials & Tribulations" Will Southern, M.D., M.S. Director of Hospitalist Services Associate Medical Director Weiler Division.
ACUTE CORONARY SYNDORME EARLY RISK STRATIFICATION Sarah Jamison March 2003.
Cardiac Enzymes By Michael W. Bowers. CK-MB 3hr, peak 12-24hr lasts 1-3 days Troponin 3-12 hrs, peak 12-24hr, lasts 8-21 days Trop-T and 7-14 Trop-I.
Myocardial infarction biomarkers Lecture 5. Cases 1 Middle aged man referred by family doctor to a dermatologist because of extensive yellow papules with.
Acute Coronary Syndrome. Acute Coronary Syndrome (ACS) Definition of ACS Signs and symptoms of ACS Gender and age related difference in ACS Pathophysiology.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
Troponins: a selective review… July 4th, 2002 ECG/Lab rounds Rob Hall PGY3.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Please press F5 on your keyboard to enter presentation mode Welcome to the Eastern Health Pathology guide to hsTnT. The information in this presentation.
Silent Ischemia STABLE CAD
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Anything that you want to know about troponins but never ask
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
ACUTE CORONARY SYNDROMES Part I. Definition Acute coronary syndrome (ACS) describes a spectrum of clinical conditions ranging from ST segment elevation.
Introduction Left bundle branch block (LBBB) is notorious for obscuring the ECG diagnosis of acute myocardial infarction (AMI) and, therefore, the decision.
Acute Coronary Syndrome David Aymond, MD. ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Ischaemic Heart Disease CASE A. CASE A: Mr HA, aged 60 years, was brought in to A&E complaining of chest pain, nausea and a suspected AMI.
Myocardial Infarction: Blood tests for diagnosis Dr Esmé Hitchcock CHEMICAL PATHOLOGIST.
Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.
Journal Club Optimizing Early Rule-Out Strategies for Acute Myocardial Infarction: Utility of 1-Hour Copeptin P. Hillinger, R. Twerenbold, C. Jaeger, K.
Antiplatelet Interventions in Acute Coronary Syndromes.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
LESSON 1 LESSON 1 Establishment of:
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Emergency Medicine Junior Teaching Programme Aberdeen Royal Infirmary Adult Syncope Evaluation in the Emergency Department Jamie Cooper Teaching 4 th March.
Chest Pain in the Emergency Department Junior Teaching C. Brown August 2015.
Cost Containment: Use of Troponin testing in the Inpatient Wards Setting Neal Kaushal, R2 DSR2, May 2013.
Acute Coronary Syndrome
Prehospital NSTEMI Patient Assessment and Treatment
Risk Stratification of Chest Pain: Best Practices
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
HEART PATHWAY Brian O’Neal, MD
Cost Effective Use of Troponin to Rule Out Acute Coronary Syndrome
Dr. Harvey White on behalf of the ACUITY investigators
Section A: Introduction
European Heart Association Journal 2007 April
Part I: A Sensible Approach to Sensitive Troponin
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
Advancing Acute Coronary Syndrome Assessment:
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
What oral antiplatelet therapy would you choose?
Update on better disease diagnosis
Presentation transcript:

Cardiac Biomarkers W. Frank Peacock, M.D., FACEP Professor, Emergency Medicine Cleveland Clinic

Biomarker? What is a biomarker? – An expensive lab test – Commonly Protein with levels that correspond to Diagnosis Prognosis – Most common method of measurement ELISA

Lab-test-ology Sensitivity TP/(TP+FN) Specificity TN/(TN+FP)

Lab-test-ology LOB LOD CV 99 th %ile

CV vs LOD Assay w LOD 5 pg/mL LOD 99 th %ile

CV and 99 th %ile 99% of the normal range for cTnI 99% Cutoff 7 pg/ml 10% CV The box of undetectableness Where is the 99 th %ile?

CV and 99 th %ile 99% of the normal range for cTnI 99% Cutoff 7 pg/ml 10% CV 20% CV 30% CV

Historical timing of cardiac necrosis markers

TIMI IIIB: Troponin I Levels Predict Mortality In UA/NSTEMI to < to < to < to < to <9.0> Risk Cardiac Troponin I (ng/ml) Ratio Mortality at 42 Days (% of Patients) Antman EA, et al. N Engl J Med. 1996;335:

2000 Emergency docs – This crap is useless in almost all patients – Only helpful if positive Rarely positive, <5% of chest pain – The rest of chest pain requires other testing Cardiologists own troponin – Tactics-TIMI 18 – IF it is detectable, it is an MI, otherwise forget it – If positive, don’t even bother thinking, just call the cath lab

C Statistic AUC = C Statistic C Stat = 50% REALLY BAD TEST C Stat = 1.0 A PERFECT Test C Stat = 75 C Stat = 0.69 OK test Area Under the Receiver Operator Characteristic (ROC) Curve

Reichlin T. N Engl J Med 2009;361: consecutive ED suspect AMI MI/USA 238 (33.1%)

ACEP Marker Recommendations Level A recommendations Don’t use markers to exclude non-AMI ACS (ie, unstable angina) Level B recommendations Use any of the following to exclude NSTEMI 8-12 hours after symptom onset –A single (-) CK-MB mass, TnI, or TnT Serial measures if < 8 hours after symptom onset –Baseline and 90 mins »A (-) myoglobin with a (-) CKMB, or (-) Tn –(-) 2-hour delta »CK-MB and Tn Can you trust them?

Historical timing of cardiac necrosis markers hsTnI

If It Moves, It Is Bad MarkerComparatorOR for 30 day MACE 95% CI  ing Tn vs. stable Troponin  ing Tn  ing CKMB vs. stable CKMB  ing CKMB Logistic regression models showing the odds ratios for predicting ACS MACE: MI, revascularization (PCI or CABG), or positive testing (>70% stenosis at catheterization, [+] MPI or non-invasive stress testing) within 30 days of index visit. McMullin N. AJEM 2009.

Event Free vs cTnT Values Days after admission to the hospital AJC 93:278, 2004 Normal <0.01  g/L Marginal <  g/L Frank elevation >0.01  g/L Cumulative proportion free of events P=0.004

STRIVE ® You can’t have it both ways…

Tn, its not just for AMI anymore

Tn Elevation w/o Overt Cardiac Ischemia Trauma contusion, ablation, pacing, ICD firings, cardioversion, endomyocardial biopsy, cardiac surgery, interventional closure of ASDs CHF Aortic valve disease and HOCM with significant LVH HTN Hypotension, often with arrhythmias Postoperative noncardiac surgery patients who seem to do well Renal failure Critically ill patients, esp with diabetes, respiratory failure, gi bleeding, sepsis Drug toxicity, eg adriamycin, 5 FU, herceptin, snake venoms, carbon monoxide poisoning Hypothyroidism Abnormalities in coronary vasomotion, including coronary vasospasm Apical ballooning syndrome Inflammatory diseases – myocarditis, eg. Parvovirus B19, Kawasaki disease, sarcoid, smallpox vaccination, or myocardial extension of BE Post PCI patients who appear to be uncomplicated Pulmonary embolism, severe pulmonary hypertension Sepsis Burns, esp if TBSA > 30% Infiltrative diseases including amyloidosis, hemachromatosis, sarcoidosis and scleroderma Acute neurological disease – CVA, subarchnoid bleeds Rhabdomyolysis with cardiac injury Transplant vasculopathy Vital Exhaustion

What now? Cardiologists are in a tizzy Cardiologists are in a tizzy All these “false positives” All these “false positives” Emergency docs think this is great Emergency docs think this is great There is no such thing as a false positive when your talking about being DEAD There is no such thing as a false positive when your talking about being DEAD

Reichlin T. N Engl J Med 2009;361: Do we really gotta be doing serial troponin’s anymore???

2012 The decade of –Will be remembered as when the cardiologists owned troponin Used to be an MI marker –Those days are gone Emergency Medicine –Taking troponin back from the cardiologists! –IT IS NOT AN AMI MARKER ANYMORE Now it’s a 14 day death marker –I don’t care about 30 days or 180 days from now –I REALLY don’t care about a year from now

Myocardial Infarction It’s a changing world An MI used to be – >40 and sweating with chest pain – Positive markers in 8-12 hours Now – It aint >40 – It aint sweating – It aint even chest pain

It would be really great if they had it written on their forehead!!

In 2011, you will miss 423,600 Acute Myocardial Infarction’s 1/3 have no chest pain Canto JG et al. JAMA. 2000;283: If you think this is the way they look…

STRIVE ® % With Chest Pain During AMI Stratified by Age SOB W&D N/V Syncope Confused

STRIVE ® 28 When your laying naked around the ER, they all look the same…… This one is having an AMI

STRIVE ® Closing Time You don’t have to go home, but you can’t stay here…. –Semisonic

STRIVE ® The ER docs challenge Admit them all: and let the insurance company sort them out… Discharge them all and let God sort them out…

STRIVE ® Emergency Medicine Roulette What % are discharged from the ED??

14 Asia-Pacific region EDs >18yo with >5 mins CP Risk stratification (blinded to care team) –TIMI<1, ECG non-dx, –Negative 0 & 2hr POC Tn, CKMB, myo Endpoint: 30 day MACE Than M. Lancet, DOI: /S (11)

STRIVE ® 33 TIMI Risk Score Risk factors: –Age  65 years –  3 risk factors for CAD –Prior coronary stenosis  50% –ST-segment deviation on ECG –  2 anginal events in last 24 hours –Use of ASA in last 7 days –Elevated serum cardiac markers CK-MB or troponin Each risk factor is assigned 1 point, and the total represents a given patient’s TIMI Risk Score 1 Event rates (all-cause mortality, MI, or urgent revascularization) increase with each 1-point increase in score (P<0.001 by chi square test for trend) 1 Number of Risk Factors 1 Rate of Composite Endpoint (Days 1-14), % 1.Antman EM et al. JAMA. 2000;284:

N=3582 –30 day MACE in 421 (11·8%) –Most often NSTEMI ADP identified 9·8% (352/3582) as low risk –3 (0·9%) had 30 day MACE Than M. Lancet, DOI: /S (11)

Potential costs savings in low risk negative ADP patients Hospital LOS –Median 26·0 h (IQR 9·9–37·0) –Mean 43·2 h (95% CI 36·2–51·2) Than M. Lancet, DOI: /S (11)

STRIVE ® He is a 67 year old, hypertensive, obese man. He took an aspirin this morning, he still smokes and has high cholesterol. Many of his family have CAD. He has been a diabetic for 15 years, and 4 years ago he had an MI. Age > 65, 3 risk factors, H/O MI, took asa: TIMI Risk score = % chance of death, MI, or UTVR in the next 14 days George is sitting in his bar at his restaurant across the street from the Emergency Department

STRIVE ® He is a 67 year old, hypertensive, obese man. He took an aspirin this morning, he still smokes and has high cholesterol. Many of his family have CAD. He has been a diabetic for 15 years, and 4 years ago he had an MI. TIMI Risk score = % chance of death, MI, or UTVR in the next 14 days George is laying in the ED, diaphoretic, with crushing CP, nauseated, BP = 100/70

Can we discharge you?? Derivation by blinded sampling (N= 703) 130 (18.5%) AMI –None w initially undetectable hs-cTnT –Sn 100.0%, NPV 100.0% 27.7% would have ‘ruled out’ for AMI –2 (1.0%) died or had AMI w/in 6 months » (1 peri-procedural AMI, 1 non-cardiac death) Validation by standard practice (N= 915) –1 patient (0.6%) with initially undetectable hscTnT developed subsequent elevation (to 17ng/L) Sn 99.8% ( ) NPV 99.4% ( ). Body, et al. JACC, 2011

European Society of Cardiology A presentation cannot R/O NSTEMI –Repeated Tn 3 hours after admit or more CP. –LOE 1B Tn is preferred over CKMB Myoglobin is not specific or sensitive enough –Is not recommended.

STRIVE ® ESC Guidelines Due to improved analytical sensitivity, low troponin levels can be detected in stable angina and in healthy patients. The mechanisms of this troponin release are not yet explained, but ANY measurable troponin is associated with an unfavourable prognosis.

Low Level Troponins One Cut-off or Two? More pg/ml cTNI Frequency Myocardial necrosis AMI Sp=99% Wait and see, do more tests AMI Sp=85%

The Now and Then of High Sensitivity Troponins Last decade Detectable Tn –99 th %ile cutpoint Great specificity Better sensitivity –No real clinical disposition impact for the ER Serial testing of less necessary Next decade Good bye specificity 2 cutpoints? Second marker –copeptin, ST-2, MPO, IMA, etc Hello sensitivity Exclude ischemia? Challenges –The role of cardiology consults –EDUCATION…………

So next time you want to get a troponin…. Risk stratify (after decide it might be ACS) You want to send that patient home? –Put on your thinking cap! –AMI? Something else? Can always repeat

Results 25 participating hospitals N=1,360 patients Overall Mean DTBT  70.1 minutes Median 100; IQR=73,138 Central lab Mean DTBT  70.5 minutes Median 103; IQR=76,141 Point of Care Mean DTBT 68.2  40.8 minutes Median 62.5, IQR=43,83.5 Peacock WF et al. Acad Emerg Med. 2004;11:569–570. Saves about 1 hour

Delay = Death N= 13,934,542 Adverse events increase with the mean LOS in similar patients in the same ED shift OR for Death if LOS ≥6 v <1 hr cohorts –Hi Acuity 1.79 Low Acuity 1.71 BMJ 2011; 342:d2983

Overcrowding = Long waits Long waits = Death N= 62,495 Risk ratio for DEATH –Per hour of ED stay = 1.1 (p < 0.001) –Per hour of ED wait = 1.2 (p=0.01) MJA 2006; 184: 208–212

Delay = Bad Care N=42,780 Long ED stays less often received guideline-recommended NSTEMI therapies Ann Emerg Med. 2007; 50;

Delay = Bad Care N=694 patientsDelayed/No antibiotics –OR 1.05 for each additional WR patient –OR 1.14 for each additional WR hour Ann Emerg Med. 2007;50:

Delay = Bad Care N=13,758 Nontreatment of pain associated with waiting room number OR = 1.03 for each additional waiting patient Ann Emerg Med. 2008;51:1-5.]

Delay = Bad Care N=162 “boarded” patients (waiting for room) Undesirable event Missed meds, lab results, arrhythmias, or other adverse events 27.8% had an undesirable event Ann Emerg Med. 2009;54: ]

14,054,431 patients: waiting = bad outcomes or death

What business intentionally kills its customers? The era of POC needing to justify itself is over. We are now in the era where the central lab must prove it is not killing our patients. If you had a way of getting data quickly, wouldn’t you?

POC vs Lab Singulex 295 MIDAS patients 155 (52.5%) NCCP 67 (22.7%) USA 61 (20.7%) NSTEMI 12 (4.1%) STEMI SensitivitySpecificity Negative Predictive Value Positive Predictive Value Area Underneath ROC curve (C-Statistic) Point of Care Alere Central Lab Singulex SnSpNPVPPVAUC POC Lab